Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 16;23(1):29.
doi: 10.1186/s13075-021-02414-0.

The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus

Lloyd Mai  1 , Arundip Asaduzzaman  1 , Babak Noamani  2 , Paul R Fortin  3 , Dafna D Gladman  1   4 , Zahi Touma  1   4 , Murray B Urowitz  1   4 , Joan Wither  5   6   7   8
Affiliations

The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus

Lloyd Mai et al. Arthritis Res Ther. .

Abstract

Objectives: Type I interferons (IFNs) play an important role in the pathophysiology of systemic lupus erythematosus (SLE). While cross-sectional data suggest an association between IFN-induced gene expression and SLE disease activity, interest in this as a biomarker of flare has been tempered by a lack of fluctuation with disease activity in the majority of patients. This led us to question whether IFN-induced gene expression might instead be a biomarker of overall disease severity, with patients with high levels spending more time in an active disease state.

Methods: Levels of five interferon-responsive genes were measured in the whole peripheral blood at baseline visit for 137 SLE patients subsequently followed for 5 years. Log transformed values were summed to yield a composite IFN5 score, and the correlation with various disease outcomes examined. Receiver operator characteristic analyses were performed for outcomes of interest. Kaplan-Meier curves were generated to compare the proportion of flare-free patients with high and low IFN5 scores over time.

Results: The baseline IFN5 score was positively correlated with the adjusted mean SLE disease activity index-2000, number of flares, adjusted mean prednisone dose, and number of new immunosuppressive medications over the subsequent 5 years. Optimal cut-offs for the IFN5 score were determined using Youden's index and predicted more severe outcomes with 57-67% accuracy. A high baseline IFN5 level was associated with a significantly increased risk of subsequent flare.

Conclusions: Measurement of the type I IFN signature is a useful tool for predicting the subsequent disease activity course.

Keywords: Disease course; Interferon; SLEDAI-2K; Systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Association between the baseline IFN5 score and disease severity in the subsequent 5 years. Correlation between the IFN5 score and specific disease outcomes. Each open circle represents an individual patient. Boxes show the Spearman correlation coefficient and p value for each outcome
Fig. 2
Fig. 2
Ability of the baseline IFN5 score to predict disease outcomes over the subsequent 5 years. ROCs are shown for various disease outcomes, with AUCs indicated
Fig. 3
Fig. 3
High IFN5 scores are associated with an increased risk of disease flare. Kaplan-Meier curves showing the proportion of flare-free patients over time. The significance of the differences between curves was determined using the Gehan-Breslow-Wilcoxon test
See this image and copyright information in PMC

References

    1. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610–2615. doi: 10.1073/pnas.0337679100. - DOI - PMC - PubMed
    1. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711–723. doi: 10.1084/jem.20021553. - DOI - PMC - PubMed
    1. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52(5):1491–1503. doi: 10.1002/art.21031. - DOI - PubMed
    1. Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA, Green SL, Utset TO. Jolly M, James JA, Harley JB, et al. Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011;63(4):1044–1053. doi: 10.1002/art.30187. - DOI - PMC - PubMed
    1. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2951–2962. doi: 10.1002/art.22044. - DOI - PubMed

Publication types

MeSH terms

Grants and funding